My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
COMPLIANCE INFO_2019
EnvironmentalHealth
>
EHD Program Facility Records by Street Name
>
G
>
GOLDEN VALLEY
>
16858
>
2200 - Hazardous Waste Program
>
PR0541023
>
COMPLIANCE INFO_2019
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
1/18/2022 12:46:32 PM
Creation date
1/18/2022 11:24:14 AM
Metadata
Fields
Template:
EHD - Public
ProgramCode
2200 - Hazardous Waste Program
File Section
COMPLIANCE INFO
FileName_PostFix
2019
RECORD_ID
PR0541023
PE
2247
FACILITY_ID
FA0023485
FACILITY_NAME
CVS PHARMACY #17412
STREET_NUMBER
16858
STREET_NAME
GOLDEN VALLEY
STREET_TYPE
PKWY
City
Lathrop
Zip
95330
CURRENT_STATUS
01
SITE_LOCATION
16858 GOLDEN VALLEY PKWY STE B
QC Status
Approved
Scanner
SJGOV\kblackwell
Tags
EHD - Public
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
108
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
58054 Federal Register/Vol. 80, No. 186/Friday, September 25, 2015/Proposed Rules <br /> is,the study investigated whether the referred to as a"bingo card."The results to 4000 containers per month to exceed <br /> concentration of warfarin in the indicate that the concentration of the the 1 kg threshold to be an LQG, <br /> residues of warfarin pill bottles was active pharmaceutical ingredient The results for nicotine residues were <br /> greater than 0.3%and therefore met the warfarin in the residues in plastic similar.For containers of gum and <br /> listing criteria for P001,or whether the bottles was usually over the 0.3% patches,the weight of total residues <br /> residues were at or below 0.3%and concentration.However,the ranged from 9-111.2 mg,although the <br /> liquid nicotine <br /> li <br /> therefore met the listing criteria for concentration of warfarin in the two containers oq <br /> U248.Although nicotine is not a residues on blister packs, including the solution contained more residues-1301 <br /> concentration-based P-listing,packaging 30-pack blister pack,was consistently and 1616 mg.Although nicotine is not <br /> from nicotine-containing products were below 0.3%.Overall,in the majority of a concentration-based listing,it is worth <br /> noting that the active pharmaceutical <br /> also investigated to determine total cases,the warfarin within the residues <br /> remaining residues. was present at a high enough ingredient of nicotine m the residues <br /> The researchers collected a total of 59 concentration to be considered Pool (33 was below the quantifiable limit of 1.5 <br /> samples containers,including 44 of 44 samples,75 percent of the µg/ml in 8 of the 15 samples and for the <br /> sample containers that had held samples). other 7 samples,the concentration of <br /> warfarin pills but had been fully sam les . nicotine ranged from 0.01--0.09%. <br /> dispensed and another been <br /> sample However,the results also confirm the iv.EPA's Office of Research and <br /> containers from nicotine-containing then15sapl! results from the first two stakeholders. Development.Finally,EPA's ORD <br /> That is,the total weight of residues conducted an analysis to evaluate <br /> products.The samples included <br /> cotne from several remaining in the containers after they whether simply removing a drug from <br /> warfarin and nii <br /> manufacturers,co range of dose were emptied of the warfarin pills is the container is equivalent to triple <br /> strengths and in various container types. negligible.For the plastic bottles,the rinsing the container.ORD's results are <br /> The residues were solvent-extracted and total weight of residue ranged from 4.3– summarized in Table 11,but the Final <br /> then dried by rotary evaporation to 82.3 mg.For the single-dose blister Project Report containing the full results <br /> determine the total weight of residues. packs,the total weight of residue ranged is in the docket for this proposed <br /> Subsequently,the residues were re- from 3.5-7.6 mg.And for the 30-pack rulemaking(EPA I3Q–RCRA-2007– <br /> dissolved in methanol and analyzed blister pack,the total weight ranged 0932).ORD analyzed three different P- <br /> using HPLC to determine the from 134.8-273 mg.Taking the smallest listed pharmaceuticals:Warfarin, <br /> concentration of the active amount of residue of 3.5 mg,it would nicotine and physostigmine salicylate. <br /> pharmaceutical within the residues, take close to 300,000 containers per Table 11 lists the 1.8 different <br /> The majority of warfarin containers month to exceed the 1 kg threshold to combinations of active pharmaceutical <br /> were plastic bottles,but some containers be an LQG.Even on the conservative ingredients,form,dosage strengths and <br /> were blister packs and three samples side,taking the largest amount of packaging combinations that ORD <br /> were 30-pill blister packs,sometimes residue of 273 mg,it would take close analyzed. <br /> TABLE 11--PHARMACEUTICAL COMBINATIONS TESTED BY EPA's ORD <br /> Active pharmaceutical Manufacturer/Brand name Form Dosage Packaging type <br /> ingredient <br /> Warfarin ..................... Taro Pharmaceutical Industries, Ltd. ............. Tablet ....... 1 mg......... Plastic bottle. <br /> Tablet ....... 5 mg......... Plastic bottle. <br /> Tablet....... 10 mg....... Plastic bottle. <br /> Tablet ....... 2 mg ......... Single-dose blister pack. <br /> Upsher-Smith/Jantoven .................................. Tablet ....... 1 mg ......... Single-dose blister pack <br /> Tablet ....... 10 mg....... Single-dose blister pack. <br /> Nicotine ...................... GlaxoSmithKlinelNicorette ............................. Gum ......... 2 mg......... Single-dose blister pack. <br /> Gum ......... 4 mg......... Single-dose blister pack. <br /> Rugby Laboratories ........................................ Gum ......... 2 mg......... Single-dose blister pack. <br /> Gum ......... 4 mg ......... Single-dose blister pack. <br /> GlaxoSmithKline/Nicorette ............................. Lozenge ... 2 mg......... Plastic vial <br /> Lozenge ... 4 mg......... Plastic vial. <br /> Rugby Laboratories ........................................ Patch........ 7 mg......... Peel-off plastic. <br /> Habitrol ....................................................:...... Patch ........ 14 mg....... Peel-Off plastic. <br /> Rugby Laboratories ........................................ Patch........ 21 mg ....... Peel-off plastic. <br /> Pfizer/Nicotrol Spray 10 mg/ml .. Glass vial. <br /> Inhaler ...... 10 mg....... Plastic container. <br /> Physostigmine Salicy- Akron Inc. ..................... Liquid 1 mg/ml .... Glass ampoule. <br /> late. <br /> All combinations in Table 11 were (2)The"maximum possible weight of (3)Thermal gravimetric analysis <br /> analyzed in triplicate using the residual drug/total residual/container" (TGA)was used to qualitatively evaluate <br /> following three-step approach: was calculated for each compound and the presence of active pharmaceutical <br /> (1)After removing the tablets,gum, packaging combination.This calculated ingredient in the residuals removed <br /> lozenges,etc from the containers,the result was used to infer a theoretical from the containers before and after <br /> amount of total residuals remaining in upper limit for the amount of active triple-rinsing. <br /> the container was determined using a pharmaceutical compound in the total With respect to the weight of the <br /> sensitive balance to weigh the container residue remaining in the container,and remaining residuals in the containers, <br /> ORD's results are similar to the results <br /> before and after triple rinsing, <br />
The URL can be used to link to this page
Your browser does not support the video tag.